Case File
efta-efta00970645DOJ Data Set 9OtherFrom: Jeffrey Epstein <jeevacation®gmail.com>
Date
Unknown
Source
DOJ Data Set 9
Reference
efta-efta00970645
Pages
2
Persons
0
Integrity
No Hash Available
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From: Jeffrey Epstein <jeevacation®gmail.com>
To: Laurie Cameron
Subject: Re: Transition to DB
Date: Thu, 12 Sep 2013 21:53:00 +0000
Ok
On Thursday, September 12, 2013, Laurie Cameron wrote:
Hi there
I hope that you are well. There are three things I'd like to review
1) I'd recommend that we let our positions at JPM run to maximize profits. JPM has told
me that if you agree, they would allow me to hold the positions to expiration and trade
around them. Unwinding them and replicating them at DB would only lead to a bid/ask
loss. JPM has no incentive to quote me good prices when they know we re closing out the
account.
The USD suffered after the lower than expected non-farm payrolls last Friday. The NZD
and AUD forwards suffered because of this and one AUD 92 Call is underwater. I will
send a p/1 tomorrow, but the position is down approx $2ook. I don't think that this will
get worse, but it would be a bad time to have to close out positions.
2) Before we execute docs with DB we need to amend the IMA to reflect that I don't need
to be registered in order to be paid and to add DB as counterpart and custodian. I can
deal directly with Darren to clean this up if you'd like.
3) I would like to ask that you pay for an independent (not from a bank)pricing model for
me to use. This is critical to keep the banks honest and pricing ultra agressive. Given my
familiarity and history with the people at JPM, I was able to make sure that their pricing
was as competitive as possible. But as a new client to DB we will not be in the same
position. A great pricing model will allow us to price, trade and reval our positions with
great accuracy. Tomorrow I am meeting with one of the premier providers of pricing
models (the same that I used at JPM and the hedge fund at which I worked after JPM)
and can provide you with more details including pricing following my meeting. Having
this pricing model will easily pay for itself over the next few months.
Thank you again and again for this opportunity. I hope that you are well.
Laurie
EFTA00970645
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA00970646
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.